Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer
Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer
复制标题
DOI：
10.1111/hpb.12199
复制
发表时间：
2014-07-01
期刊：
影响因子：
2.9
通讯作者：
Mulvihill, Sean J.
中科院分区：
文献类型：
--
作者：
Kendrick, Zachary W.;Firpo, Matthew A.;Mulvihill, Sean J.
背景：诊断和预后生物标志物的鉴定是改善胰腺导管腺癌（PDAC）治疗的研究重点。胰岛素样生长因子结合蛋白 2 (IGFBP2) 和间皮素 (MSLN) 已显示出作为其他癌症血清生物标志物的潜力，但尚未在 PDAC 中进行充分研究。方法：通过酶联免疫吸附测定 (ELISA) 对 84 名 PDAC 患者、84 名健康对照受试者和 40 名慢性胰腺炎 (ChPT) 患者组成的队列中的血清 IGFBP2 和 MSLN 水平进行定量。回归模型将 IGFBP2 和 MSLN 水平与诊断、性别、年龄、分期和生存相关。结果：与 ChPT 和健康对照样本相比，在年龄调整模型中，IGFPB2 和 MSLN 血清水平可诊断 PDAC（分别为 P = 0.032 和 P = 0.002）。在 95% 特异性阈值下，IGFBP2 的敏感性为 22%，MSLN 的敏感性为 17%。这两种蛋白质均未达到 CA 19-9 的诊断准确性。然而，IGFBP2 或 MSLN 或两者都正确识别了 CA 19-9 错误识别的 28 个样本中的 18 个。在年龄调整模型中，血清 IGFBP2 (P = 0.36) 和 MSLN (P = 0.29) 都不是生存的显着预测因子。讨论：血清 IGFBP2 和 MSLN 各自是较弱的诊断分类器，但在诊断生物标志物组中可能有用。
Background: Identification of diagnostic and prognostic biomarkers is a research priority for the improved management of pancreatic ductal adenocarcinoma (PDAC). Insulin-like growth factor binding protein 2 (IGFBP2) and mesothelin (MSLN) have shown potential as serum biomarkers in other cancers, but have not been adequately studied in PDAC.Methods: Serum IGFBP2 and MSLN levels were quantified by enzyme-linked immunosorbent assay (ELISA) in a cohort of 84 PDAC patients, 84 healthy control subjects and 40 chronic pancreatitis (ChPT) patients. Regression models related IGFBP2 and MSLN levels to diagnosis, gender, age, stage and survival.Results: IGFPB2 and MSLN serum levels were diagnostic for PDAC in age-adjusted models (P = 0.032 and P = 0.002, respectively) when compared with ChPT and healthy control samples. At a 95% specificity threshold, the sensitivity for IGFBP2 was 22% and the sensitivity for MSLN was 17%. Neither protein approached the diagnostic accuracy of CA 19-9. However, IGFBP2 or MSLN or both correctly identified 18 of the 28 samples misidentified by CA 19-9. In age-adjusted models, neither serum IGFBP2 (P = 0.36) nor MSLN (P = 0.29) were significant predictors of survival.Discussion: Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel.